Chordoma Foundation

Author Archives: Chordoma Foundation Team


Turning vision into action through empowered philanthropy: Get to know Kenny Brighton

Our Head of Philanthropy, Kenny Brighton, was initially drawn to the Foundation through a personal experience with chordoma — the diagnosis, journey, and eventual loss of his uncle Mike, who fought a heroic battle with the disease for many years. He knows our community because he IS our community, and he shares our urgency for sound scientific solutions and reliable support for chordoma families.
Continue reading

2019 Annual Report: Going ALL IN

Our 2019 Annual Report details how a confluence of recent research advances have cleared a path to identify existing treatments that could help chordoma patients in the near-term, and, incredibly, created a line of sight to the first treatments that strike at the Achilles’ heel of chordoma. It also tells how many in our community have rallied behind our recently-launched $16M ALL IN campaign to bring these unprecedented research opportunities to fruition, while at the same time helping patients and families confront chordoma with confidence and get the best care possible along every step of their journey. Continue reading

Chordoma community invited to participate in the Natural History Study of Rare Solid Tumors

The ongoing challenges presented by the COVID-19 pandemic have interrupted and altered medical research across the globe. While some scientists have had to halt their studies abruptly, others can forge ahead thanks to virtual options. The chordoma community is one of many rare disease communities invited to participate in one such study, the Natural History Study of Rare Solid Tumors, currently underway at the National Cancer Institute (NCI). Continue reading

The Chordoma Foundation and The Mark Foundation for Cancer Research fund open-source research to accelerate drug discovery following recent breakthroughs

The Chordoma Foundation (CF) and The Mark Foundation for Cancer Research (MFCR) announced today a two-year, $1.4M partnership with a team of researchers at three institutions to develop new treatments for chordoma, a rare and difficult-to-treat bone cancer. The researchers will focus on creating the first drugs to inhibit a protein known as brachyury. Continue reading



Pin It on Pinterest

Comodo SSL